Literature DB >> 17264754

Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics?

ShouWei Han1, Jesse Roman.   

Abstract

Peroxisome proliferator-activated receptors are ligand-activated intracellular transcription factors that have been implicated in important biological processes such as inflammation, tissue remodeling and atherosclerosis. Emerging information also implicates peroxisome proliferator-activated receptors in oncogenesis. Peroxisome proliferator-activated receptor gamma, the best studied of the peroxisome proliferator-activated receptors, modulates the proliferation and apoptosis of many cancer cell types, and it is expressed in many human tumors including lung, breast, colon, prostate and bladder. Natural and synthetic agents capable of activating peroxisome proliferator-activated receptor gamma have been found to inhibit cancer cell growth in vitro and in animal models. These agents, however, are not specific and both peroxisome proliferator-activated receptor gamma-dependent and peroxisome proliferator-activated receptor gamma-independent pathways involved in their effects have been identified. Together, these studies, coupled with a few clinical trials, suggest that peroxisome proliferator-activated receptor gamma is a novel target for the development of new and effective anticancer therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17264754     DOI: 10.1097/CAD.0b013e328011e67d

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  48 in total

1.  Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.

Authors:  Shing Hwa Liu; Chin Chang Shen; Yu Chiao Yi; Jaw Ji Tsai; Chih Chien Wang; Ju Ting Chueh; Keh Liang Lin; Tso Ching Lee; Hung Chuan Pan; Meei Ling Sheu
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.

Authors:  Jordi Rodon; Victoria DeSantos; Robert Jean Ferry; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  The metabolism of proline as microenvironmental stress substrate.

Authors:  James M Phang; Jui Pandhare; Yongmin Liu
Journal:  J Nutr       Date:  2008-10       Impact factor: 4.798

Review 4.  Cancer and diet: How are they related?

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Afsaneh Lavasanifar; Bharat B Aggarwal
Journal:  Free Radic Res       Date:  2011-06-09

5.  Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells.

Authors:  Chan Woo Cheon; Dae Hwan Kim; Dong Heon Kim; Yong Hoon Cho; Jae Hun Kim
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

6.  C/EBPalpha redirects androgen receptor signaling through a unique bimodal interaction.

Authors:  J Zhang; M Gonit; M D Salazar; A Shatnawi; L Shemshedini; R Trumbly; M Ratnam
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

7.  The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.

Authors:  C Filion; T Motoi; A B Olshen; M Laé; R J Emnett; D H Gutmann; A Perry; M Ladanyi; Y Labelle
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

8.  Nelfinavir suppresses insulin signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones.

Authors:  Debasis Mondal; Kai Liu; Milton Hamblin; Joseph A Lasky; Krishna C Agrawal
Journal:  Ochsner J       Date:  2013

9.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

10.  Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer.

Authors:  Jordi Tauler; James L Mulshine
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.